Ascentage Pharma to Present Lisaftoclax Data at ASH 2025
In a registrational Phase II study of 72 evaluable patients with relapsed/refractory CLL/SLL after BTK inhibitor exposure, lisaftoclax monotherapy...
Adaptive Clinical Trial Design Adaptive Trial Design Addiction Psychiatry AI in Clinical Trials alcohol use disorder Alzheimer's Disease Article Clinical Operations Clinical Research Clinical Trial Design Clinical Trial Operations Clinical Trial Ops Brief Clinical Trials CLINOPS WATCHDOG CNS Drug Development CNS Trials Conference Coverage Decentralized Clinical Trials Digital Health Technologies dual diagnosis eClinical Tech News eClinical Technology EMA Executive Interviews FDA Enforcement FDA Guidance FDA Real-World Evidence FDA Regulation FDA Regulatory Strategy FDA Warning Letter GCP Compliance GLP-1 Receptor Agonists Ketamine Therapy Oncology Trials Opinion Parkinson's Disease Platform Trials Psilocybin MDMA Psychedelic Clinical Trials PSYCH PULSE Real-World Evidence site activation Site Operations study startup Treatment-Resistant Depression
In a registrational Phase II study of 72 evaluable patients with relapsed/refractory CLL/SLL after BTK inhibitor exposure, lisaftoclax monotherapy...
At the SCOPE 2025 Europe conference, during a panel titled, “Trials Are Leaving Europe — Can We Bring Them...
Early Phase 1b signals from Fulcrum’s PIONEER study suggest pociredir, an oral EED inhibitor, increases fetal hemoglobin to levels...
In pooled 8‑week induction data from the Phase 3 ABTECT‑1 and ABTECT‑2 trials in moderate‑to‑severe ulcerative colitis, 37% of...
Three-year follow-up from Ascendis Pharma’s PaTH Forward (Phase 2) and PaTHway (Phase 3) trials in adults with chronic hypoparathyroidism...
Topline data: In the non-randomized AVG cohort (n=112) of Merit Medical’s WAVE trial, WRAPSODY Cell-Impermeable Endoprosthesis achieved a 6-month...
Gelteq has initiated a preclinical animal study with the Monash University Institute of Pharmaceutical Sciences to evaluate a gel-based...
Prior clinical data for NT-0796 reported rapid reductions of about 80% in IL-6, fibrinogen, and hsCRP in patients at...
In preclinical studies, once-daily oral dosing of BMF-650 in obese cynomolgus monkeys produced dose-dependent reductions in food intake and...
IN8bio reported preclinical data showing that its pan-γδ T cell engager, INB-619, achieved complete B cell depletion in systemic...